Author

Zhao Yang

Institution: Amgen (United States)

Observed institution: Amgen (United States)

ORCID: 0000-0002-1199-1052

Observed ORCID: 0000-0002-1199-1052

OpenAlex ID: A5030908830

Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

2023 · William K. Kelly, Daniel C. Danila, et al. · Cancer Discovery · 121

Trial in progress (XALute): Phase 3 study of xaluritamig vs investigator’s choice of cabazitaxel or second androgen receptor directed therapy (ARDT) in post-taxane metastatic castration-resistant prostate cancer (mCRPC).

2025 · William Kevin Kelly, Michael J. Morris, et al. · Journal of Clinical Oncology · 4

Abstract 727: Association of baseline tumor and peripheral biomarker features with efficacy in metastatic castration-resistant prostate cancer patients treated with xaluritamig

2025 · Benjamin E. Decato, Zhao Yang, et al. · Cancer Research · 2

Data from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

2024 · William K. Kelly, Daniel C. Danila, et al. · 1

Supplementary Table S1 from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

2024 · William K. Kelly, Daniel C. Danila, et al. · 1

Salvage Therapy Outcomes in a Historical Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia

2018 · Farhad Ravandi, Sherry A. Pierce, et al. · Blood · 1

Supplementary Methods from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

2024 · William K. Kelly, Daniel C. Danila, et al.

Supplementary Figure S2 from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

2024 · William K. Kelly, Daniel C. Danila, et al.

Supplementary Figure S1 from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

2024 · William K. Kelly, Daniel C. Danila, et al.

Supplementary Table S2 from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

2024 · William K. Kelly, Daniel C. Danila, et al.

Supplementary Figure S2 from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

2024 · William K. Kelly, Daniel C. Danila, et al.

Data from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

2024 · William K. Kelly, Daniel C. Danila, et al.

Supplementary Table S1 from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

2024 · William K. Kelly, Daniel C. Danila, et al.

Supplementary Methods from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

2024 · William K. Kelly, Daniel C. Danila, et al.

Supplementary Table S2 from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

2024 · William K. Kelly, Daniel C. Danila, et al.

Supplementary Figure S1 from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

2024 · William K. Kelly, Daniel C. Danila, et al.

Carfilzomib (K) in relapsed and refractory multiple myeloma (RRMM): frailty subgroup analysis from phase 3 ASPIRE and ENDEAVOR

2019 · Thierry Facon, Ruben Niesvizky, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 17

Citation count: 130

H-index: 2

I10-index: 1